AJR49,,112023 ASSEMBLY JOINT RESOLUTION 49 May 25, 2023 - Introduced by Representatives Murphy, Cabrera, Drake, Ohnstad, Rozar, Shankland, Sinicki and Clancy, cosponsored by Senators Cabral-Guevara, Cowles, Roys and Spreitzer. Referred to Committee on Rules.
AJR49,,22Relating to: designating Hypertrophic Cardiomyopathy Awareness Day and efforts to educate people about hypertrophic cardiomyopathy. AJR49,,33Whereas, Hypertrophic Cardiomyopathy (HCM) is a chronic cardiovascular disease involving thickening of the heart muscle and can potentially lead to debilitating symptoms and serious complications including heart failure, atrial fibrillation, stroke, and in rare cases sudden cardiac death; and AJR49,,44Whereas, HCM is the most common inheritable heart disease and can affect anyone regardless of age, gender, or ethnicity with a reported prevalence ranging from 1 in 200 to 1 in 500 in the general population; and AJR49,,55Whereas, an estimated 700,000 to 1,650,000 people in the United States have HCM, yet 85 percent of them may remain undiagnosed; and AJR49,,66Whereas, HCM shares symptoms with other common cardiovascular and pulmonary diseases, such as shortness of breath, chest pain, fatigue, palpitations, and fainting, making it difficult to distinguish HCM from these other diseases; and AJR49,,77Whereas, all-cause mortality risk is three to four times higher in patients with HCM than that of the general population; and AJR49,,88Whereas, knowing one’s medical history and any signs and symptoms of HCM is an important first step in receiving an accurate diagnosis of HCM; and AJR49,,99Whereas, a healthcare provider must conduct a thorough screening with cardiac health questions to help identify a risk of cardiac disorders both genetic and congenital; and AJR49,,1010Whereas, a health-care provider may conduct several tests, including an echocardiogram, a cardiac MRI, or genetic testing to confirm a family history of HCM, and must examine the heart to diagnose HCM; and AJR49,,1111Whereas, following a diagnosis of HCM, it is important for patients to work with their healthcare provider to learn more about their disease and understand different management options, including prescription medicines and surgical treatment options that may help; and AJR49,,1212Whereas, the fourth Wednesday in February is an appropriate day to observe Hypertrophic Cardiomyopathy Awareness Day; now, therefore, be it AJR49,,1313Resolved by the assembly, the senate concurring, That the Wisconsin Legislature designates the fourth Wednesday in February of each year as “Hypertrophic Cardiomyopathy Awareness Day” in Wisconsin in order to raise public awareness about hypertrophic cardiomyopathy; and, be it further AJR49,,1414Resolved, That the Wisconsin Legislature acknowledges the critical importance of hypertrophic cardiomyopathy awareness to improve cardiovascular health in Wisconsin; and, be it further AJR49,,1515Resolved, That the Wisconsin Legislature supports raising awareness of the consequences of undiagnosed and untreated hypertrophic cardiomyopathy and the need to seek appropriate care for hypertrophic cardiomyopathy as a serious public health issue; and, be it further AJR49,,1616Resolved, That the Wisconsin Legislature respectfully requests the Governor to issue annually a proclamation recognizing the fourth Wednesday in February in as “Hypertrophic Cardiomyopathy Awareness Day” in Wisconsin and calls upon the people in this state to observe the day with appropriate programs and activities.
